List of Excipients in Branded Drug TOLSURA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	FD&C BLUE NO. 1
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	GELATIN
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	HYPROMELLOSE PHTHALATE
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	MAGNESIUM STEARATE
Mayne Pharma Commercial LLC	TOLSURA	itraconazole	51862-462	METHYLENE CHLORIDE

Tolsura Excipient Strategy and Commercial Opportunities in Itraconazole Formulation

Last updated: August 17, 2026

Tolsura is a differentiated itraconazole capsule built around Mayne Pharma’s SUBA-Itraconazole formulation platform. Its commercial value depends on improved dissolution and absorption relative to conventional itraconazole capsules, rather than on a new active ingredient. The central excipient opportunity is the manufacture and supply of polymer-based amorphous solid dispersions, particularly the excipient system used to improve itraconazole solubility, dissolution, and exposure.

Tolsura is FDA-approved for the treatment of blastomycosis and histoplasmosis in adults and for the treatment of aspergillosis in adults who are intolerant of amphotericin B or are refractory to amphotericin B therapy.[1] It contains 65 mg of itraconazole per capsule and is marketed by Mayne Pharma.

What is Tolsura and how does its formulation differ from conventional itraconazole?

Tolsura uses SUBA-Itraconazole, a formulation technology designed to increase itraconazole dissolution and systemic exposure. Itraconazole is highly lipophilic and practically insoluble in water. Its conventional capsule formulations have historically shown variable absorption that is affected by gastric acidity, food intake, and gastrointestinal conditions.

SUBA-Itraconazole reduces the particle-size and dissolution limitations associated with crystalline itraconazole. The formulation uses an amorphous dispersion approach in which itraconazole is dispersed within a hydrophilic polymer matrix. The result is a higher apparent solubility and more consistent dissolution profile.

Attribute	Tolsura	Conventional itraconazole capsule
Active ingredient	Itraconazole	Itraconazole
Strength	65 mg per capsule	Commonly 100 mg per capsule
Formulation platform	SUBA-Itraconazole	Conventional itraconazole pellet or capsule formulation
Primary formulation objective	Improved dissolution and exposure	Delivery of crystalline itraconazole
FDA pathway	505(b)(2) application	Original NDA or generic ANDA
Therapeutic category	Systemic triazole antifungal	Systemic triazole antifungal
Biosimilar exposure	None	None
Principal formulation risk	Amorphous-dispersion stability and dissolution control	Variable absorption and food or pH effects

FDA labeling reports that Tolsura provides higher exposure than conventional itraconazole capsules at comparable clinical doses, allowing lower total itraconazole milligram dosing in specified regimens.[1]

Which excipients are strategically important in Tolsura?

The most commercially important excipient is the polymer used to maintain itraconazole in an amorphous, rapidly dissolving state. Publicly available product information identifies a formulation containing itraconazole with polymeric and functional excipients that support dispersion, flow, capsule filling, and release performance.[1,2]

The strategy can be divided into four excipient functions.

1. Polymer matrix for amorphous solid dispersion

A hydrophilic polymer is used to disperse itraconazole and suppress recrystallization. Hypromellose-based polymers, including hypromellose acetate succinate or related pharmaceutical dispersion polymers, are commercially relevant to this formulation class.

The polymer must provide:

• High compatibility with itraconazole
• Sufficient drug loading
• Rapid wetting and dissolution
• Resistance to recrystallization
• Acceptable residual-solvent and moisture performance
• Consistent particle morphology after spray drying or another dispersion process

For excipient suppliers, the opportunity is not limited to material sales. Tolsura-type products require technical support covering grade selection, viscosity, substitution patterns, spray-drying behavior, and long-term solid-state stability.

2. Surfactant and wetting system

A surfactant can improve wetting of the hydrophobic drug-polymer matrix. Poloxamers and similar nonionic surfactants are relevant because they can improve dissolution without introducing the precipitation behavior associated with some ionic surfactants.

Commercial risks include:

• Peroxide formation
• Batch-to-batch impurity variation
• Interaction with the polymer matrix
• Impact on capsule-shell compatibility
• Changes in dissolution after accelerated stability testing

Surfactant suppliers with pharmaceutical-grade documentation, low peroxide specifications, and strong change-control systems have an advantage in this segment.

3. Bulking, flow, and capsule-filling excipients

Microcrystalline cellulose and related fillers can support powder flow, dose uniformity, and capsule-filling performance. Silicon dioxide may be used as a glidant. Disintegrants can be necessary when the product depends on rapid dispersion of the amorphous matrix after capsule rupture.

These materials are less differentiated than the dispersion polymer, but they remain important because a change in particle-size distribution, moisture content, or bulk density can affect:

• Content uniformity
• Capsule weight variation
• Disintegration
• Dissolution
• Manufacturing throughput

4. Capsule-shell and color-system components

The hard gelatin capsule introduces a secondary excipient system. Gelatin grade, moisture, shell opacity, titanium dioxide status, colorants, and printing inks can affect stability and visual identification.

For a formulation containing an amorphous dispersion, capsule-shell moisture is a material-control issue. Excess moisture can alter the physical state of the dispersion, while insufficient moisture can increase shell brittleness. Suppliers with low-moisture packaging and validated capsule-shell controls can capture value in contract manufacturing and supply agreements.

What formulation patents protect Tolsura?

Tolsura’s protection is centered on the SUBA-Itraconazole formulation platform rather than composition-of-matter protection for itraconazole. Itraconazole is an established active ingredient, so commercial exclusivity depends on formulation patents, regulatory exclusivity, trademarks, manufacturing know-how, and clinical positioning.

Public patent records associated with Mayne Pharma and SUBA-Itraconazole include U.S. patents directed to itraconazole pharmaceutical compositions and delivery systems. U.S. Patent No. 10,238,657 is publicly associated with itraconazole composition technology and has been cited in connection with the Tolsura product.[3] Orange Book listings and patent-term calculations should be checked against the current FDA database because listed patents, expiration dates, pediatric adjustments, and certifications can change.[4]

The protected technical concepts generally include:

• Amorphous itraconazole dispersions
• Itraconazole-polymer ratios
• Enhanced dissolution formulations
• Multiparticulate or capsule delivery systems
• Stabilization against recrystallization
• Manufacturing processes for producing the dispersion

How strong is the Tolsura patent estate?

The estate is stronger than a conventional formulation patent limited to a capsule composition if the claims cover the physical state of itraconazole, polymer selection, dissolution performance, and manufacturing parameters. The principal vulnerability is design-around activity.

A generic or 505(b)(2) applicant could attempt to use:

• A different polymer
• A different drug-to-polymer ratio
• A separate spray-drying process
• A hot-melt extrusion process
• A nanocrystal or lipid-based delivery system
• A different capsule or tablet dosage form

The commercial question is whether the alternative can match Tolsura’s exposure and clinical labeling while avoiding the asserted claims. Because itraconazole pharmacokinetics are formulation-sensitive, a technically different product may face substantial bioequivalence and clinical-development costs even if it avoids literal patent infringement.

When does Tolsura lose exclusivity?

Tolsura does not have biologic exclusivity and is not protected by an active-ingredient patent for itraconazole. Its exclusivity profile is therefore based on formulation patents, FDA regulatory exclusivity, and commercial barriers.

The FDA approved Tolsura in October 2018 under a 505(b)(2) application.[1] The product received regulatory exclusivity associated with the approval, but that exclusivity period does not extend beyond the relevant statutory period. The longer-term barrier is the listed formulation patent estate.

Exclusivity component	Tolsura position
Active-ingredient patent	No meaningful remaining U.S. composition-of-matter protection
FDA pathway	505(b)(2)
New-drug exclusivity	Time-limited regulatory exclusivity
Formulation patents	Principal long-term protection
Biosimilar protection	Not applicable
Generic pathway	ANDA or 505(b)(2), depending on product and labeling strategy
Trademark	Tolsura brand protection is separate from patent protection

Any precise generic-entry date depends on the current Orange Book listing, patent-term adjustment, pediatric exclusivity, Paragraph IV certifications, litigation, and settlement terms. A filing date alone does not establish an authorized launch date.

What is the Orange Book status of Tolsura?

Tolsura is an FDA-approved small-molecule drug product that may be listed in the Orange Book with patents covering its formulation or method of use.[4] The relevant Orange Book analysis should distinguish among:

1. Patents listed against the 505(b)(2) product.
2. Patents covering the formulation itself.
3. Patents covering approved methods of use.
4. Regulatory exclusivity that has already expired.
5. Any patent litigation triggered by an ANDA Paragraph IV certification.

A generic applicant challenging an Orange Book-listed patent would typically submit a Paragraph IV certification stating that the patent is invalid, unenforceable, or will not be infringed. The NDA holder could then bring patent litigation within the statutory window, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[5]

Which companies could challenge Tolsura?

Potential challengers fall into three groups.

Generic itraconazole manufacturers

Companies with existing itraconazole manufacturing capabilities could pursue a conventional capsule or an alternative formulation. A conventional 100 mg itraconazole capsule would not automatically be substitutable for Tolsura because the products have different strengths, dosing instructions, exposure profiles, and formulation technology.

Specialty pharmaceutical companies

A specialty company could pursue a 505(b)(2) product using a distinct dispersion, lipid formulation, tablet, or oral suspension. The commercial value would depend on proving comparable exposure and obtaining a label that competes with Tolsura in systemic fungal infections.

Excipient and contract-development companies

CDMOs with spray-drying, hot-melt extrusion, solid-state characterization, and capsule-filling capabilities could support a design-around program. The most valuable capabilities include:

• Spray-dried dispersion development
• XRPD, DSC, and dynamic-vapor-sorption testing
• Dissolution method development
• In vitro-in vivo correlation
• Scale-up under GMP conditions
• Polymer and surfactant screening
• Moisture-controlled packaging

What commercial opportunities exist in Tolsura excipients?

Qualified polymer supply

The highest-value opportunity is the supply of pharmaceutical-grade dispersion polymers. A supplier can differentiate through regulatory files, multi-site manufacturing, narrow viscosity specifications, low residual impurities, and demonstrated compatibility with itraconazole.

Second-source development

Tolsura-type products have supply-chain exposure because the dispersion polymer, surfactant, and specialized manufacturing process may each have limited qualified sources. A second-source program could reduce supply risk, but changing an excipient may require comparability data, stability studies, dissolution bridging, and regulatory submissions.

Generic design-around platforms

A supplier or CDMO could develop an alternative itraconazole platform using:

• HPMCAS or another cellulose-derived polymer
• Povidone or copovidone
• Soluplus-type amphiphilic polymers
• Lipid-based self-emulsifying systems
• Nanocrystalline itraconazole
• Hot-melt-extruded dispersions

The strongest opportunity is an excipient platform that can produce equivalent exposure with a lower drug load, reduced food effect, and a manufacturing process that avoids Tolsura patent claims.

Pediatric and hospital dosage forms

Itraconazole has unmet formulation needs in patients who cannot swallow capsules. Potential products include oral granules, powder for reconstitution, oral suspension, and smaller-strength capsules. These products would face dose-uniformity, palatability, precipitation, and stability requirements.

A pediatric or hospital formulation could compete without directly replicating Tolsura’s capsule architecture, although it would still require careful patent and regulatory analysis.

Regional licensing

Mayne Pharma has commercialized Tolsura in the United States, while itraconazole products are marketed globally by multiple companies. Regional opportunities may exist for licensing formulation technology outside the United States, especially where systemic fungal infections are treated in immunocompromised populations and conventional itraconazole exposure is difficult to manage.

Geographic freedom-to-operate analysis must cover:

• U.S. formulation patents
• European patents and national validations
• Patent term and supplementary protection certificates
• Local regulatory exclusivity
• Manufacturing-site rights
• Distribution and trademark rights

What manufacturing and intellectual-property barriers affect Tolsura competitors?

The main manufacturing barrier is reproducibility of the amorphous dispersion. A product may meet assay specifications while failing dissolution or stability requirements because itraconazole recrystallizes during storage.

Critical process variables include:

• Feed concentration
• Spray-drying temperature
• Atomization conditions
• Solvent composition
• Polymer-to-drug ratio
• Residual moisture
• Milling and particle-size distribution
• Encapsulation force and fill weight

The principal IP barrier is claim scope. A competitor must assess whether its polymer, drug loading, solid-state form, dissolution profile, and process steps fall within issued claims. A non-infringing product may still face FDA requirements for comparative pharmacokinetics and clinical justification.

How does Tolsura compare with Sporanox and generic itraconazole?

Tolsura’s commercial positioning is based on formulation performance, not a novel mechanism of action.

Product	Formulation proposition	Main commercial advantage	Main weakness
Tolsura	SUBA-Itraconazole dispersion	Higher and more consistent exposure with lower capsule strength	Higher product cost and formulation-patent exposure
Sporanox capsules	Conventional itraconazole formulation	Established clinical history and broad recognition	Food, acidity, and absorption variability
Generic itraconazole capsules	Conventional or approved generic formulation	Lower acquisition cost	May not be substitutable for Tolsura
Itraconazole oral solution	Solubilized oral formulation	Alternative administration and absorption profile	Different tolerability and dosing considerations

Automatic pharmacy substitution depends on FDA therapeutic-equivalence ratings and product-specific requirements. A generic conventional itraconazole capsule is not interchangeable with Tolsura merely because both contain itraconazole.

Key Takeaways

• Tolsura is a 65 mg SUBA-Itraconazole capsule approved through the 505(b)(2) pathway.
• Its core commercial differentiation is an amorphous solid-dispersion formulation that improves itraconazole dissolution and exposure.
• Dispersion polymers are the most valuable excipient category, followed by surfactants, flow aids, disintegrants, and moisture-controlled capsule components.
• The patent estate protects formulation and manufacturing concepts rather than a new itraconazole molecule.
• Generic competition is technically feasible but must address formulation-specific pharmacokinetics, patent scope, and FDA requirements.
• The strongest commercial opportunities are qualified polymer supply, second-source development, design-around formulations, specialty CDMO services, and pediatric or hospital dosage forms.
• Tolsura has no biosimilar risk. Its competitive risk is from ANDA or 505(b)(2) products.

FAQs

Can a conventional itraconazole generic substitute for Tolsura?

Not automatically. Tolsura has a different strength and formulation technology. Substitution depends on FDA therapeutic-equivalence determinations and applicable state pharmacy rules.

Which excipient is most important to Tolsura performance?

The dispersion polymer is the most important excipient because it controls itraconazole’s amorphous state, dissolution, and resistance to recrystallization.

Is Tolsura protected by a composition-of-matter patent?

No meaningful remaining U.S. active-ingredient protection is expected for itraconazole. Tolsura relies on formulation, process, regulatory, and trademark protection.

Could a nanocrystal itraconazole product compete with Tolsura?

Yes, technically. A nanocrystal product could pursue a different dissolution strategy, but it would need to establish clinical performance and address formulation-patent claims.

Does Tolsura have biosimilar competition?

No. Itraconazole is a chemically synthesized small molecule. Competition would arise through generic or 505(b)(2) pathways, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2018). Tolsura (itraconazole) capsules, prescribing information.
2. Mayne Pharma. (2023). Tolsura product information and SUBA-Itraconazole technology materials.
3. U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,238,657, pharmaceutical compositions comprising itraconazole.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).